Cirrhosis
Background
A generally irreversible fibrotic scaring of the liver parenchyma.
Differential
- Hepatitis chronic B and C
- Alcoholic liver disease
- Non-alcoholic steatohepatitis
- Drug induced (ie. Tylenol)
- Cardiac Cirrhosis
- Primary biliary cirrhosis
- Primary sclerosing cholangitis
- Autoimmune Hepatitis
- Alpha1 anti-trypsin Deficiency
- Cystic Fibrosis
Clinical Features
+1 | +2 | +3 | |
---|---|---|---|
Bilirubin | <2 mg/dL | 2-3 mg/dL | >3 Mg/dL |
Albumin | >3.5 mg/dL | 2.8-3.5 mg/dL | <2.8 mg/dL |
INR | <1.7 | 1.7-2.2 | >2.2 |
Ascites | No ascites | Ascites, medically controlled | Ascites, poorly controlled |
Encephalopathy | No encephalopathy | Encephalopathy, medically controlled | Encephalopathy, poorly controlled |
- Score ≤ 7 = Class A = 100% and 85% one and two-year patient survival
- Score 7 - 9 = Class B = 80% and 60% one and two-year patient survival
- Score ≥ 10 = Class c = 45% and 35% one and two-year patient survival
MELD-Na Score | 3-month mortality |
---|---|
40 | 71.3% |
30-39 | 52.6% |
20-29 | 19.6% |
10-19 | 6.0% |
<9 | 1.9% |
Complications of cirrhosis
- Ascites
- Esophageal varices
- Hepatic encephalopathy
- Spontaneous bacterial peritonitis
- Hepatorenal syndrome
- Portal hypertension
- Hepatocellular carcinoma
Management
Disposition
- ↑ Child CG, Turcotte JG. Surgery and portal hypertension. In: The liver and portal hypertension. Edited by CG Child. Philadelphia: Saunders 1964:50-64
- ↑ Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001 Feb;33(2):464-70.